Introduction
Prostate cancer has been globally expanding placing a high burden on patient-reported health-related quality of life (HRQoL). Recently, prostate cancer has become the second mostly diagnosed male cancer with a rising incidence by 3% annually for the last 5 years. According to SEER data, an estimated 288,300 new prostate cancer patients will be diagnosed in 2023 representing approximately 14% of all new cancer cases [1]. Metastatic disease accounts for 6–8% of newly diagnosed prostate cancer cases [2].
Upfront combination treatments that have been greatly encouraged and adopted in the management of metastatic prostate cancer patients have negatively impacted upon health-related quality of life (HRQoL) [3]. Short-term and long-term HRQoL should be considered before choosing the most tailored treatment for metastatic prostate cancer patients [4].
Anzeige
Prostate-directed radiotherapy is a new standard practice that has shown substantial benefits in delaying disease progression and improving survival outcomes (5, 6). However, combining prostate radiotherapy with the standard androgen-deprivation therapy affects patients’ physical, emotional, sexual, and social health. Ultimately, HRQoL after local radiotherapy depends on the total dose, fractionation regimen and the dose received by the critical organs [7].
Early genitourinary toxicities may include obstructive and irritative symptoms such as frequency, nocturia and urgency. Early gastrointestinal toxicities include diarrhea, rectal bleeding, and abdominal pain. These symptoms typically disappear within 4–8 weeks after finishing prostate radiotherapy. However, some patients might suffer from proctitis with rectal bleeding as a late rectal toxicity. Less commonly patients might suffer hematuria as a late bladder toxicity [8].
Undoubtedly, assessing health-related quality of life facilitates improved treatment outcomes. Focusing on reporting various quality of life domains, including urinary, sexual and bowel functions for each patient is associated with improved survival outcomes [9, 10]. Thus, standardizing HRQoL assessment tools, their scoring and interpretation in metastatic prostate cancer patients receiving prostate radiotherapy is necessary to optimize treatment outcomes and improve patients’ adherence to treatment and health care facilities [9]. In addition to using validated patient-reported outcome measures (PROMs) to evaluate HRQoL, reporting radiotherapy-related adverse events is complementary to assess patients’ tolerability and treatment efficacy. This study aimed to assess the impact of delivering cytoreductive local radiotherapy concurrently with ADT on patient reported HRQoL. We hypothesized that administering cytoreductive prostate radiotherapy to metastatic prostate cancer patients would lead to an improvement in health-related quality of life outcomes.
Methods
Study design and conduct
A phase III randomized controlled study was conducted from November 2020 to November 2022 at the Clinical Oncology Department, Suez Canal University Hospital in Ismailia, Egypt. The study aimed to assess the patient-reported HRQoL and toxicity profile in metastatic prostate cancer patients who received local prostate-directed radiotherapy concurrent with ADT. The study protocol was approved by the Research Ethics Committee at the Faculty of Medicine, Suez Canal University prior to its commencement. All patients provided written informed consent before enrollment and had the right to withdraw from the study at any time.
Anzeige
Patients
This study encompassed eligible patients with either de-novo or metachronous metastatic prostate cancer, defined according to the European Society for Radiotherapy (ESTRO) and the European Organization for Research and Treatment of Cancer (EORTC) criteria for oligometastatic disease [11]. Patients with histologically proven adenocarcinoma and a performance score ≤ 2 according to the Eastern Cooperative Oncology Group (ECOG) performance scale, with or without nodal involvement, low metastatic burden prostate cancer (< 4 bone metastases), or high metastatic burden prostate cancer (≥ 4 bone metastases at least 1 beyond spine or pelvis, ± visceral metastases) according to CHAARETED definition. Patients were excluded if they had a second neoplasm, ECOG performance score > 2, underwent radical prostatectomy, received prior pelvic radiotherapy, or had cerebral metastases. We recruited and enrolled 70 patients at our institution between November 2020 and November 2022. Then, 63 patients were randomly allocated to receive either prostate radiotherapy concurrent with ADT (Prostate RT group) or the standard ADT (control group).
Randomization and masking
Randomization was conducted using computer generated block randomization with a block size of 4 which consisted of 2 treatments with 2 patients per treatment. Stratification of patients at randomization was not performed, and allocation was not masked due to the nature of the intervention.
Intervention
All patients with metastatic prostate cancer received the standard ADT (Gonadotropin hormone–releasing hormone agonist ± bicalutamide) or underwent orchiectomy 2 months prior to randomization. ADT was subsequently administered concurrently with radiotherapy and continued thereafter. Local external beam radiotherapy was administered as one of two regimens either: conventional regimen 70 Gy in 35 daily fractions of 2 Gy over 7 weeks, or hypofractionated regimen 55 Gy in 20 daily fractions of 2.75 Gy over 4 weeks. Patients were simulated in supine position with an empty rectum and comfortably full bladder. Pelvic immobilization was maintained using knee support. Planning CT scans were acquired without intravenous contrast. We employed forward planned three-dimensional (3D) conformal radiotherapy with planning target volume (PTV) that encompassed the prostate with a 10 mm margin circumferentially, except posteriorly (6 mm) and the proximal 2 cm of seminal vesicles. Elective pelvic nodal irradiation was not included in the field. Patients were followed-up weekly during radiotherapy, then 1 month after finishing radiotherapy, then every 3 months for a year.
All patients were then requested to complete the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Prostate Module (EORTC-QLQ-PR25) at baseline and then every 3 months throughout the study. Patient reported outcome measures (PROMs) were filled in and registered using paper forms. This module consists of multi-item scales designed to measure prostate cancer-specific health-related quality of life outcomes (Supplementary File. 1). The module comprises 25 questions, all of which should be completed by the patient. We used this questionnaire to assess baseline HRQoL in metastatic prostate cancer patients receiving standard of care and to determine changes in patient-reported HRQoL after prostate radiotherapy [10]. The questions in the prostate cancer module are grouped into symptom scales and functional scales. The symptoms scales assess urinary symptoms (Questions 1–7,9), incontinence aid (Question 8), bowel symptoms (Questions 10–13) and hormonal treatment-related symptoms (Questions 14–19). The functional scales consist of questions related to sexual activity (Questions 20,21) and sexual functioning (Questions 22–25). Scoring of the EORTC QLQ-PR25 was carried out according to the provided EORTC scoring manual (Supplementary File. 2) [10]. The calculated raw score for each scale is linearly transformed into a scale from 0 to 100 points. Higher scores on symptomatic scales indicate greater symptom severity whereas higher scores on functioning scales indicate better levels of functioning.
During treatment, early and late genitourinary and gastrointestinal toxicity symptoms were reported weekly. After treatment, these symptoms were reported every 3 months during regular follow-up visits or when serious adverse events occurred, and these events were graded according to the Radiation Therapy Oncology Group (RTOG) scale. Early toxicity was recorded within the first 90 days post-radiation while late toxicity was recorded after 90 days. The metastatic burden of the disease was assessed through CT and bone scans. Radiographic response after radiation was monitored every 6 months using CT chest and pelvi-abdominal scans and evaluated based on the RECIST 1.1 criteria [12].
Endpoints
The primary endpoint of this study was patient-reported health-related quality of life (HRQoL). Secondary endpoints included early and late radiation toxicity for the prostate-radiotherapy group and radiographic progression-free survival.
Statistical analysis
The target sample size was calculated as 50 patients. This provided 80% power (one-sided-α of 0.025). Statistical analysis was conducted using the Statistical Package for Social Science (SPSS), version 28 (IBM Corporation, Armonk, NY, USA). The statistical significance of the difference between mean scores between the prostate radiotherapy group and the control group was tested using independent-sample t test. Friedman’s test was used to compare mean HRQoL scores between baseline and different time points post-radiation for one year. We managed missing data by performing a complete-case analysis, which involved excluding items related to censored or lost follow-up patients. Additionally, we addressed the missing items in the scale through imputation method.
Fisher’s exact test and Pearson’s Chi square test were conducted to test for the significance of association between variables. Radiographic progression-free survival was measured using Cox Regression analysis and the Log-Rank test was used for comparison between study groups. The hazard ratio and its 95% confidence interval were calculated using multivariate Cox regression to determine the association between variables and radiographic progression-free survival. The statistical significance for radiographic progression-free survival was measured using the Wilcoxon signed rank test. Post-hoc survival analysis was conducted to correlate radiographic progression-free survival with the metastatic burden of the disease. Additionally, exploratory subgroup analysis was performed to compare the median radiographic progression-free survival time among different subgroups. Subgroup analyses were pre-specified for the baseline metastatic volume (low vs. high), the response to androgen deprivation (castration sensitive vs. resistant) and the received radiotherapy regimen (conventional 70 Gy vs. hypofractionated 55 Gy). All statistical tests were two-sided, and p-values of < 0.05 were considered statistically significant.
Anzeige
Results
From November 23, 2020, to November 21, 2022, a total of 63 patients were enrolled and randomly assigned to either the control group receiving standard ADT (n = 29) or the radiotherapy group receiving standard ADT and radiotherapy (n = 34). Among the radiotherapy group, 20 patients received the hypofractionated radiation schedule, while the remaining 14 patients received the conventional fractionation schedule. Only one patient in the conventional fractionation group stopped treatment after receiving 11 sessions due to severe cardiac comorbidity (Fig. 1). We used the CONSORT Patient reported outcomes (PROs) extension checklist for reporting PROs.
The study groups were well balanced regarding baseline sociodemographic and clinicopathological characteristics.
Fig. 1
CONSORT flow diagram
×
![]()
The median age of patients was 70 years (IQR 66–75). The most common histopathological variant in both study groups was acinar adenocarcinoma (88.9%). The most frequent histological grade observed was GS 8–10 (47.6%). The most common pathological stages were T3 (38.1%) and N0 (61.9%). The most common site of metastases was bone (69.8%). The radiotherapy group had a significantly higher incidence of nodal positive disease (p = 0.035). High-volume metastatic disease was present in 63.5% of patients in both groups, and most patients had synchronous metastatic disease (85.7%). Most patients in both groups had an ECOG performance score of 1 (65.1%). Clinically, most patients suffered frequency (87.3%), urgency (95.2%), difficulty (88.9%), and dysuria (84.1%). Patients in the control group had significantly more skeletal-related events than those in the radiotherapy group (62.1%, p = 0.001). The median duration of androgen deprivation therapy administered before randomization was 4.25 months (IQR 2.5-9) for the radiotherapy group and 2.8 months (IQR 1.94-7) for the control group. Most patients received combined GnRH agonist and bicalutamide (71.4%). The majority of patients were castrate sensitive (68.3%), while 31.7% were castrate resistant. Docetaxel was received by 25.4% of patients in both groups, whereas 22.2% received abiraterone acetate. Very few patients received enzalutamide (4.8%) (Table 1).
Anzeige
Table 1
Sociodemographic and clinicopathological characteristics among study groups
Variables | Prostate RT group n = 34 (54%) | Control group n = 29 (46%) | P-value |
|---|---|---|---|
Age (years) < 65 | 10 (29.4%) | 4 (13.8%) | 0.224 f |
> 65 | 24 (70.6%) | 25 (86.2%) | |
Median (IQR) | 68 (64–72) | 73 (68.5–79.5) | |
Marital status Married | 24 (70.6%) | 14 (48.3%) | 0.068 f |
Single | 10 (29.4%) | 15 (51.7%) | |
Residence Rural | 10 (29.4%) | 11 (37.9%) | 0.478 |
Urban | 24 (70.6%) | 18 (62.1%) | |
Histopathological variant Acinar adenocarcinoma | 32 (94.1%) | 24 (82.8%) | 0.233 f |
Others | 2 (5.9%) | 5 (17.2%) | |
GS ≤ 7 | 12 (35.3%) | 4 (13.8%) | 0.081 f |
8–10 | 22 (64.7%) | 25 (86.2%) | |
T Stage T2 | 13 (38.2%) | 8 (27.6%) | 0.371 |
T ≥ 3 | 21 (61.8%) | 21 (72.4%) | |
N Stage N0 | 17 (50%) | 22 (75.9%) | 0.035* |
N+ | 17 (50%) | 7 (24.1%) | |
Site of metastases Bones | 23 (67.6%) | 21 (72.4%) | 0.628 f |
Lungs | 2 (5.9%) | ||
> 1 site | 9 (26.5%) | 8 (27.6%) | |
Metastatic burden High metastatic burden | 18 (52.9%) | 22 (75.9%) | 0.060 |
Low metastatic burden | 16 (47.1%) | 7 (24.1%) | |
Timing of Metastases Synchronous | 27 (79.4%) | 27 (93.1%) | 0.160 f |
Metachronous | 7 (20.6%) | 2 (6.9%) | |
Performance status | |||
≤ 1 | 25 (73.5%) | 17 (58.6%) | 0.211 |
2 | 9 (26.5%) | 12 (41.4%) | |
Prior ADT Duration, median (IQR) | 4.25 (2.5-9) | 2.8 (1.9-8) | 0.073 |
GnRH agonist only | 3 (8.8%) | 5 (17.2%) | 0.453 f |
Bicalutamide only | 6 (17.6%) | 3 (10.3%) | 0.488 f |
Both | 25 (73.5%) | 21 (72.4%) | 0.921 |
Response to ADT Castration naïve/sensitive | 24 (70.6%) | 19 (65.5%) | 0.666 |
Castration resistant | 10 (29.4%) | 10 (34.5%) | |
Docetaxel | 7 (20.6%) | 9 (31%) | 0.342 |
Abiraterone acetate | 10 (29.4%) | 4 (13.8%) | 0.224 f |
Enzalutamide | 2 (5.9%) | 1 (3.4%) | 1.000 f |
Palliative RT | 9 (26.5%) | 25 (86.2%) | < 0.001* |
Comorbidities* | 22 (64.7%) | 19 (65.5%) | 0.946 |
After a median follow-up duration of 12 months (IQR 10–14), there was a significant improvement in urinary and bowel functions at 3 months, 6 months, and 12 months intervals compared to baseline. However, there was a statistically significant worsening of ADT related symptoms, sexual activity, and sexual functioning at 3 months, 6 months, and 12 months intervals compared to baseline (Table 2).
Table 2
Health-related Quality of life scoring of the prostate radiotherapy group over one year
EORTC QLQ-PR25 | Mean (SD) | P-value |
|---|---|---|
Urinary functions Baseline | 76.76 (15.1) | < 0.001* |
3 months | 15.06 (17.32) | |
6 months | 12.02 (15.15) | |
9 months | 12.02 (15.15) | |
12 months | 11.22 (15.17) | |
Incontinence aid Baseline | 14.10 (31.51) | 0.144 |
3 months | 10.26 (26.28) | |
6 months | 11.54 (29.73) | |
9 months | 11.54 (29.73 | |
12 months | 11.54 (29.73) | |
Bowel functions Baseline | 13.78 (10.26) | < 0.001* |
3 months | 10.26 (5.92) | |
6 months | 8.79 (5.74) | |
9 months | 8.33 (5.78) | |
12 months | 8.33 (5.78) | |
ADT-related symptoms Baseline | 57.1 (17.11) | < 0.001* |
3 months | 60.47 (17.87) | |
6 months | 63.03 (17.98) | |
9 months | 64.74 (18.52) | |
12 months | 64.96 (18.51) | |
Sexual activity Baseline | 32.05 (18.81) | < 0.001* |
3 months | 18.27 (14.72) | |
6 months | 16.34 (14.24) | |
9 months | 13.78 (10.53) | |
12 months | 13.46 (10.56) | |
Sexual function Baseline | 14.10 (12.42) | < 0.001* |
3 months | 3.53 (5.86) | |
6 months | 3.53 (5.86) | |
9 months | 3.53 (5.86) | |
12 months | 3.53 (5.86) |
Patients in the prostate radiotherapy group had statistically significantly lower and better scores in urinary symptoms and ADT related symptoms than patients in the control group at 3 months, 6 months, 9 months, and 12 months (p < 0.001) (Table 3).
Anzeige
Table 3
Comparing health-related quality of life domains scoring between study groups
QLQ-PR25 Variables | Prostate RT group | Control group | P-value |
|---|---|---|---|
Mean (SD) | Mean (SD) | ||
QoL Urinary functions | |||
Baseline | 78.19 (15.11) | 77.44 (14.58) | 0.844 |
3 months | 18.75 (20.25) | 62.19 (15.67) | < 0.001* |
6 months | 15.19 (17.33) | 59.24 (18.20) | < 0.001* |
9 months | 12.5 (14.96) | 61.04 (20.56) | < 0.001* |
12 months | 11.22 (15.17) | 59.29 (22.89) | < 0.001* |
QoL Bowel functioning | |||
Baseline | 15.44 (11.26) | 8.33 (8.34) | 0.707 |
3 months | 12.5 (9.7) | 13.58 (14.83) | 0.738 |
6 months | 11.02 (8.97) | 11.96 (13.02) | 0.756 |
9 months | 8.63 (5.78) | 13.33 (13.63) | 0.108 |
12 months | 15.38 (20.93) | 14.08 (17.12) | 0.114 |
QoL Incontinence aid | |||
Baseline | 16.67 (83.34) | 31.03 (44.48) | 0.147 |
3 months | 13.54 (30.36) | 25.93 (38.49) | 0.173 |
6 months | 11.83 (29.25) | 20.29 (31.37) | 0.313 |
9 months | 10.71 (28.77) | 21.67 (34.67) | 0.239 |
12 months | 11.54 (29.73) | 28.21 (38.12) | 0.142 |
QoL ADT symptoms | |||
Baseline | 58.33 (16.08) | 68.01 (10.46) | 0.006* |
3 months | 62.33 (17.04) | 75.72 (6.19) | < 0.001* |
6 months | 64.87 (17.36) | 77.05 (4.53) | < 0.001* |
9 months | 65.87 (18.31) | 78.61 (4.52) | 0.001* |
12 months | 64.96 (18.51) | 79.06 (5.15) | 0.001* |
QoL Sexual activity | |||
Baseline | 28.92 (18.03) | 12.64 (12.32) | < 0.001* |
3 months | 16.40 (13.96) | 9.88 (11.56) | 0.058 |
6 months | 14.78 (13.56) | 8.7 (12.17) | 0.095 |
9 months | 13.1 (10.5) | 6.67 (11.34) | 0.053 |
12 months | 13.46 (10.56) | 7.69 (11) | 0.121 |
QoL Sexual functioning | |||
Baseline | 12.26 (11.83) | 2.3 (5.41) | < 0.001* |
3 months | 2.86 (5.44) | 2.47 (4.51) | 0.765 |
6 months | 2.96 (5.51) | 1.89 (3.57) | 0.431 |
9 months | 3.27 (5.71) | 0.83 (2.56) | 0.081 |
12 months | 3.53 (5.86) | 0.64 (2.31) | 0.097 |
Furthermore, there was no statistically significant difference between patients who received either fractionation regimens in terms of early or late genitourinary and gastrointestinal events. The most observed significant acute GU toxicity in both fractionation arms was cystitis (G2 in 58.8% and G3 + in 32.3%). Acute G2 hematuria developed in 38.2% and G3 + in 32.3% of patients. Acute G2 urinary obstruction occurred in 2.9% and G3 + in 32.3% of patients (Table 4).
Meanwhile, acute proctitis and abdominal pain were the most common acute GI toxicities in both fractionation schedules, with G2 toxicity occurring in 32.3% of patients and G3 + in 14.7%. Acute G2 diarrhea was reported in 8.8% of patients, and G3 + in 3 patients (8.8%). Patients who received the hypofractionation regimen experienced a higher-grade acute diarrhea. In addition, acute anal fissure/fistula was detected in 3 patients (8.8%), with 2 patients developing acute anal fissure and one patient developing acute perianal fistula. Acute G3 + rectal bleeding developed in 3 patients (8.8%) (Table 4).
The most common late GU toxicities observed in both fractionation schedules were late cystitis and bladder spasm, with G2 toxicity occurring in 6.4% of patients and G3 + in 12.9%. Late hematuria was reported as G2 in 3.2% of patients and G3 + in 12.9%. Four patients (12.9%) developed late G3 + urinary obstruction, and all patients in both arms experienced erectile dysfunction.
The most prevalent late GI toxicities in both fractionation schedules were proctitis and abdominal pain, with G2 toxicity occurring in 3.2% of patients and G3 + in 3.2%. Additionally, late rectovesical fistula developed in 1 patient (3.2%) (Table 4).
Table 4
Incidence of significant genitourinary and gastrointestinal toxicities in patients receiving prostate radiotherapy
Toxicity | Fractionation type | P-value | |
|---|---|---|---|
Conventional n = 14 (41.2%) | Hypofractionation n = 20 (58.8%) | ||
Acute GU toxicity G2+ | 12 (85.7%) | 19 (95%) | 0.555 f |
Cystitis, bladder spasm G2 | 9 (75%) | 11 (57.9%) | 0.452 f |
G3+ | 3 (25%) | 8 (42.1%) | |
Hematuria G2 | 6 (66.7%) | (46.7%) | 0.423 f |
G3+ | 3 (33.3%) | 8 (53.3%) | |
Obstruction G2 | 0 (0%) | (12.5%) | 1.000 f |
G3+ | 4 (100%) | 7 (87.5%) | |
Acute GI toxicity G2+ | 7 (50%) | 9 (45%) | 0.774 |
Diarrhea G2 | 3 (100%) | 0.100 f | |
G3+ | 3 (100%) | ||
GI upset G2 | 4 (100%) | 1 (25%) | 0.143 f |
G3+ | 3 (75%) | ||
Proctitis, Abdominal pain G2 | 6 (85.7%) | 5 (55.6%) | 0.308 f |
G3+ | 1 (14.3%) | 4 (44.4%) | |
Fissure/ fistula G3+ | 2 (14.3%) | 1 (5%) | 0.555 f |
Rectal bleeding G3+ | 2 (14.3%) | 1 (5%) | 0.555 f |
Late GU toxicity G2+ | 2 (16.7%) | 3 (17.6%) | 1.000 f |
Cystitis, bladder spasm G2 | 1 (33.3%) | 1 (33.3%) | 1.000 f |
G3+ | 2 (66.7%) | 2 (66.7%) | |
Hematuria G2 | 1 (33.3%) | 1.000 f | |
G3+ | 2 (100%) | 2 (66.7%) | |
Obstruction G3+ | (16.7%) | 2 (11.8%) | 1.000 f |
Erectile dysfunction | 11 (100%) | 17 (100%) | |
Late GI toxicity G2+ | 1 (9.1%) | 1(5.9%) | 1.000 f |
Proctitis, Abdominal pain G2 | 1 (100%) | 1.000 f | |
G3+ | 1 (100%) | ||
Fissure/ fistula G3+ | 1 (9.1%) | 0.393 f | |
For the radiotherapy group, the median radiographic progression-free survival was not reached, compared to 4.067 months for the control group. The radiotherapy group had a significantly longer radiographic progression-free survival than the control group (not reached vs. 4.067 months, Log-rank p < 0.001), with a risk of radiographic progression that was 0.167 times that of the control group (HR: 0.167, 95% CI 0.081–0.344; p < 0.001) (Fig. 2).
Fig. 2
Kaplan-Meir curve of radiographic progression-free survival among study groups
×
![]()
Further confirmatory subgroup analysis revealed that low volume metastatic patients in the radiotherapy group had a significantly lower risk of radiographic progression compared to those in the control group (HR: 0.029, 95% CI 0.003–0.244; p=0.004). Similarly, high-volume metastatic patients in the radiotherapy group had a significantly lower risk of radiographic progression than those in the control group (HR: 0.343, 95% CI 0.160–0.739; p=0.006). Furthermore, the metastatic castration-sensitive patients who received radiotherapy had a significantly lower risk of radiographic progression than those in the control group (HR: 0.096, 95% CI 0.032–0.292; p < 0.001) (Fig. 3).
Fig. 3
Forest plot for subgroup analysis of progression-free survival
×
![]()
The multivariable analysis of radiographic progression-free survival in subgroups receiving prostate radiotherapy showed that radiographic progression-free survival was significantly associated with the low volume metastatic subgroup (adjusted HR: 0.104, 95% CI 0.013–0.857; p = 0.035) but non significantly associated with the castration-sensitive subgroup (adjusted HR: 0.305, 95% CI 0.083–1.117; p = 0.073) or the hypofractionation regimen subgroup (adjusted HR: 0.650, 95% CI 0.185–2.287; p = 0.502) (Table 5).
Table 5
Univariate and Multivariate subgroup analysis of radiographic progression-free survival in prostate radiotherapy group
Subgroup | Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|---|
HR | P-value | 95% CI | HR | P-value | 95% CI | |||
Lower | Upper | Lower | Upper | |||||
Metastatic burden | ||||||||
Low metastatic burden | 0.091 | 0.023* | 0.012 | 0.716 | 0.104 | 0.035* | 0.013 | 0.857 |
High metastatic burden | 1 | 1 | ||||||
Response to ADT | ||||||||
Castration sensitive | 0.233 | 0.021* | 0.068 | 0.805 | 0.305 | 0.073 | 0.083 | 1.117 |
Castration resistant | 1 | 1 | ||||||
Fractionation | ||||||||
Hypofractionation | 0.740 | 0.621 | 0.226 | 2.433 | 0.650 | 0.502 | 0.185 | 2.287 |
Conventional | 1 | 1 | ||||||
We conducted a post-hoc analysis which showed that the median radiographic progression-free survival was significantly higher and not reached in the low volume and castration-sensitive metastatic subgroups compared to the high-volume and castration-resistant metastatic subgroups (p = 0.004, p = 0.012). The risk of radiographic progression among patients in the low volume metastatic subgroup who received prostate radiotherapy was 0.091 times the risk among patients in the high-volume subgroup. No significant difference was found between the two fractionation schedules in terms of median radiographic progression-free survival (p = 0.620).
Discussion
This study was a randomized controlled trial aimed at investigating the benefits of adding prostate radiotherapy to standard androgen deprivation therapy in metastatic prostate cancer patients. We aimed at evaluating the patient-reported health-related quality of life outcomes and the tolerability of prostate radiotherapy in these patients. In this study, we stratified metastatic prostate cancer patients according to their disease burden, classifying them as either having high or low burden metastatic disease. In contrast, Boevé et al. subgrouped their patients based on the number of bone lesions, with < 5, 5–15, or more bone lesions, as determined by bone scan and conventional imaging. They did not stratify patients at the time of randomization [13]. However, Parker et al. also stratified their patients into low and high burden metastatic disease groups based on the metastatic burden at randomization [14].
Prostate radiotherapy was administered to a larger proportion of patients with high-volume metastatic disease in our study compared to Parker et al. and Boevé et al. Our objective was to deliver cytoreductive radiotherapy to their primary prostate with the aim of disrupting the communication pathways between the primary tumor and metastases, impeding the spread of cancer cells to more distant sites, and consequently retarding disease progression. In this subset of patients, we also intended to attain local control of disabling urinary symptoms, thereby positively impacting their health-related quality of life.
With regard to radiation dose, we delivered the same conventionally fractionated regimen of 70 Gy in 35 fractions over 7 weeks, as prescribed by Boevé et al. Alternatively, we delivered the same hypofractionated regimen of 55 Gy in 20 daily fractions over 4 weeks, as prescribed by Parker et al. Apart from the therapeutic benefit, radiobiological rationale, and good local response to the hypofractionated schedule, there were several advantages, such as shortening overall treatment time, saving medical resources, and improving patient convenience [5, 14].
Certainly, an isoeffective hypofractionated treatment regimen (60 Gy/20fx) could be more effective and feasible in metastatic hormone sensitive patients. However, the delivery of this isotoxic escalated dose would mandate the use of more advanced Intensity modulated radiation therapy (IMRT) or Stereotactic ablative body radiotherapy (SABR) techniques to prescribe this isotoxic dose without exceeding the predetermined normal tissue tolerance limits. Unfortunately, these high precision radiotherapy modalities weren’t available in our center.
We preferred using the EORTC QLQ PR-25 as an assessment tool for HRQoL outcome as it focuses on disease specific local disabling symptoms and radiation treatment related adverse events. Several randomized controlled studies also utilized the EORTC QLQ C-30 scale [15, 16]. The EORTC QLQ C-30 includes more generalized, non-symptom specific items on its scale. Our primary concern was to assess local symptoms both before and after radiation therapy and to evaluate radiation treatment effects which were more comprehensively illustrated in EORTC QLQ PR-25 scale.
Monitoring early and late side effects following prostate radiotherapy and their impact on patient’s quality of life is essential for understanding HRQoL. Our results showed that the HRQoL of our patients seems to be at a high level including urinary and bowel functions except for sexual functioning. However, the deterioration in sexual activity and functioning which developed after a time could be a negative consequence of long-term ADT. In contrast, Boevé et al. concluded that patients reported significantly more diarrhea, bowel symptoms, and urinary symptoms after receiving prostate radiotherapy and ADT compared to ADT alone (p < 0.001) [17]. Corresponding to our findings, Parker et al. reported that prostate radiotherapy did not negatively impact HRQoL, with no differences in quality-of-life scores over time [6].
Regarding acute and late toxicities, our data showed that acute significant G3 or higher (G3+) genitourinary adverse events were detected in 32.3% of patients in the prostate radiotherapy group. Additionally, acute significant G3 + gastrointestinal adverse events occurred in 14.7% of patients after radiotherapy. On the other hand, late significant G3 + genitourinary adverse events were detected in 12.9%, whereas late significant G3 + gastrointestinal adverse events were seen in 3.2% of patients after radiotherapy. Our study reported more significant G3 + acute and late genitourinary and acute gastrointestinal adverse events than reported by Parker et al. The late significant G3 + genitourinary toxicity was observed in 2% of their patients within 1 year of prostate radiotherapy. Late significant G3 + gastrointestinal toxicities were comparably reported for 3% of their patients [6]. This can be attributed to more patients receiving systemic treatment and the absence of IMRT technique in our centre. Contrary to our study, in which all patients were treated with 3D conformal radiotherapy, Cho et al. reported that 71% of their patients were treated with IMRT, and none of them developed significant gastrointestinal or genitourinary toxicity [18].
The effect of prostate radiotherapy on sexuality exhibited considerable variability among our patients. While some men experienced a complete loss of erectile function, others encountered milder or temporary difficulties. This variability could be attributed to factors such as age, baseline sexual function and comorbidities.
Several randomized controlled trials have consistently shown that cytoreductive prostate radiotherapy, especially when combined with androgen deprivation therapy (ADT), can result in erectile dysfunction for a significant portion of patients. The severity of sexual dysfunction may fluctuate, yet it tends to be more pronounced in patients receiving higher radiation doses and undergoing prolonged ADT durations [19].
Furthermore, the regression analysis demonstrated the significant impact of delivering prostate radiotherapy on radiographic progression-free survival in metastatic prostate cancer patients. Consistent with our findings, Boevé et al. showed that the median progression-free survival was statistically significantly associated with low metastatic volume disease (HR: 0.15, p = 0.005) and castration-sensitive disease (HR: 0.22, p = 0.004) [20].
Our prespecified subgroup analysis revealed that prostate radiotherapy improved progression-free survival in low metastatic volume (HR: 0.029, p = 0.004), high metastatic volume (HR: 0.343, p = 0.006), and metastatic castration-sensitive disease (HR: 0.096, p < 0.001). Meanwhile, Parker et al. found that prostate radiotherapy improved failure-free survival in all patients (HR: 0.76, p < 0.0001) and progression-free survival in patients with low metastatic burden (HR: 0.78, p < 0.0001) after a median follow-up of 37 months [14]. Parallel to our data, Parker et al. reported that symptomatic local progression was improved with prostate radiotherapy in the low metastatic burden group [6]. However, Burdett et al. showed that there was no improvement in progression-free survival with prostate radiotherapy [21].
Regarding palliative bone-directed radiotherapy, we treated symptomatic patients similarly to the ORIOLE study conducted by Phillips et al. which demonstrated the clinical and survival benefit of additional treatment of all oligometastases [22]. Likewise, Cho et al. and Morgan et al. also permitted oligometastases directed radiotherapy in addition to prostate radiotherapy [18, 23]. This contradicts Parker et al. and Boevé et al., who did not consider palliative bone-directed radiotherapy [13, 14]. Currently, ESTRO recommends metastases-directed radiotherapy strategies and focuses on the role of combination treatments in oligometastatic prostate cancer patients, as declared by Zilli et al. [24] .
There were some limitations in our study. First, the small sample size may affect its external validity. Second, the lack of highly advanced precision radiation techniques such as IMRT in our center was an important limitation. Besides, we did not require the use of PSMA-PET due to limited resources in our center, although PSMA-PET is more accurate.
and precise in initial staging than conventional imaging [25, 26]. Additionally, the presence of missing data could pose a challenge, potentially introducing bias into our analysis. Lastly, it’s worth noting that HRQoL assessments frequently depend on self-reported data from patients. This subjectivity could introduce bias, as patients might interpret and respond to questions differently based on their personal experiences and perceptions.
Conclusion
In conclusion, the administration of prostate radiotherapy to metastatic prostate cancer patients can improve patient-reported health-related quality of life outcomes, particularly urinary function with bowel function preservation. The HRQoL after prostate radiotherapy in metastatic prostate cancer patients correlates with the total delivered dose, fractionation regimen and beam delivery techniques. Most acute radiation-induced toxicities were transient and manageable without significant long-term effects. We recommend that this study can be replicated with a larger sample size and longer follow-up duration to assess potential late effects in patients who received prostate radiotherapy and their impact on HRQoL.
Understanding the quality of life in metastatic prostate cancer patients after prostate radiotherapy is vital for healthcare providers. It helps them make informed shared decisions about treatment options, manage side effects, and provide support services that address the specific needs and concerns of each patient, ultimately improving their overall well-being and survivorship. Additionally, novel studies are awaited to test the long-term health-related quality of life outcomes of combination therapies as part of a treatment intensification plan for metastatic hormonal-sensitive prostate cancer patients.
Acknowledgements
We thank patients who agreed to participate in this research. We also thank the head of the Department of Clinical Oncology, the medical staff and the radiation physicists’ team at Suez Canal University Hospital for facilitating this work.
Declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
Ethical approval for this study was obtained from the Research Ethics Committee at the Faculty of Medicine, Suez Canal University (approval number: 4492) on 1 March 2020. All participants provided informed consent prior to participation in the study, and the study was conducted in accordance with the principles of the Declaration of Helsinki.
Consent for publication
Not applicable.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.